SciELO - Scientific Electronic Library Online

 
vol.87 issue2Relationship of Interleukin-6 G-174C and G-572C and Interleukin-1 C-511T and C+3953T Polymorphisms with Ischemic Cardiomyopathy in Quito, EcuadorMechanisms of Dysfunction and Prognostic Markers in Bicuspid Aortic Valve author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista argentina de cardiología

On-line version ISSN 1850-3748

Abstract

SANTOS, DANIEL A. et al. Cardiotoxicity Alerts during Treatment with Trastuzumab in Breast Cancer at Four-year Follow-up. Rev. argent. cardiol. [online]. 2019, vol.87, n.2, pp.103-108.  Epub Mar 01, 2019. ISSN 1850-3748.  http://dx.doi.org/10.7775/rac.es.v87.i2.13799.

Background:

Adjuvant treatment of HER2+ breast cancer includes adriamycin and trastuzumab, a monoclonal antibody that produces cardiotoxicity. The actual epidemiologic impact of trastuzumab-related cardiotoxicity in unselected populations in Argentina remains unknown.

Objectives:

The aim of this study was to evaluate the impact of trastuzumab-related cardiotoxicity during adjuvant treatment for breast cancer in an unselected population after >12 months of completing therapy.

Methods:

Among 888 patients prospectively evaluated for breast cancer, 231 (38%) were HER2+ and received adjuvant therapy with adriamycin and trastuzumab. Left ventricular ejection fraction was evaluated before treatment, after completing adriamycin and then every 3 months during follow-up. Cardiotoxicity was defined as a decline in left ventricular ejection fraction >10%, according to the definition of the American College of Cardiology and was compared with the definitions of the B-31 trial and the MD Anderson Cancer Center.

Results:

A decline in left ventricular ejection fraction >10% from baseline values occurred in 65% (n=150) of the patients during a mean follow-up of 48±12 months. In the per group analysis, patients included in the B-31and MD Anderson Cancer Center vs. the American College of Cardiology definitions presented greater percent fall in left ventricular ejection fraction during treatment: 20% vs. 20% vs. 16%, respectively (p<0.04) and ended treatment with left ventricular ejection fraction <50% in 42% vs. 41% vs. 33% of cases, respectively (p=0.01).

Conclusions:

In the population treated with trastuzumab under cardio-oncology surveillance during 48±12 months:

1 - Left ventricular ejection fraction was significantly decreased in more than 60% of patients.

2 - Different guidelines show different cardiotoxicity risks which demands continuous cardio-oncological monitoring.

Keywords : Cardiotoxicity; Trastuzumab; Breast cáncer.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )